Antibody Drug Conjugate (ADC) service platform
Category: Gene & Biotech Services
Exhibitor: EIRGENIX INC.
Booth No: M724A
Antibody drug conjugates (ADC) are now a viable and effective therapy for cancer and hematological diseases.Three ADC drugs have been approved and more than 20 others are in the clinical trial stage. ADC's major approach is to target cancer cells directly by linking high potentcy chemicals (eg. derivatives of toxins) onto monoclonal antibodies. This approach enhances potency and reduces toxic side effects by targeting the monoclonal antibody to specific cells. There are three key components in developing ADC: a specific monoclonal antibody, a high potency chemical, and an effective linker. EirGenix is strategically partnering with Formosa Laboratories Inc. providing integrated service platform to support our clients’ biologics by providing the best monoclonal antibodies, high potency chemicals, and effective linkers.
Contract Research (CRO) & QC Analysis Service
Contract Development & Manufacturing (CDMO) Service
Cell Line Development & Cell Banking Service
Products you may be interested in